Seagen (Seagen) Inventory Turnover : 0.32 (As of Sep. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Seagen Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Seagen's Cost of Goods Sold for the three months ended in Sep. 2023 was $165 Mil. Seagen's Average Total Inventories for the quarter that ended in Sep. 2023 was $509 Mil. Seagen's Inventory Turnover for the quarter that ended in Sep. 2023 was 0.32.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Seagen's Days Inventory for the three months ended in Sep. 2023 was 281.07.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Seagen's Inventory-to-Revenue for the quarter that ended in Sep. 2023 was 0.78.

Seagen Inventory Turnover Historical Data

The historical data trend for Seagen's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seagen Inventory Turnover Chart

Seagen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Inventory Turnover

Get a 7-Day Free Trial

1.56

0.63

2.15

1.97

1.31

Seagen Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Inventory Turnover	Get a 7-Day Free Trial															0.32	0.27	0.25	0.37	0.32

Seagen Inventory Turnover Calculation

Seagen's Inventory Turnover for the fiscal year that ended in Dec. 2022 is calculated as

	Inventory Turnover (A: Dec. 2022 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2022 )	/ (	(Total Inventories (A: Dec. 2021 )	+	Total Inventories (A: Dec. 2022 ))	/	count )
=	410.058	/ (	(200.663	+	427.211)	/	2 )
=	410.058	/	313.937
=	1.31

Seagen's Inventory Turnover for the quarter that ended in Sep. 2023 is calculated as

	Inventory Turnover (Q: Sep. 2023 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Sep. 2023 )	/ (	(Total Inventories (Q: Jun. 2023 )	+	Total Inventories (Q: Sep. 2023 ))	/	count )
=	165.254	/ (	(486.854	+	531.188)	/	2 )
=	165.254	/	509.021
=	0.32

Seagen (NAS:SGEN) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Seagen's Days Inventory for the three months ended in Sep. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2023 )	/	Cost of Goods Sold (Q: Sep. 2023 )	*	Days in Period
	=	509.021	/	165.254	*	365 / 4
	=	281.07

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Seagen's Inventory to Revenue for the quarter that ended in Sep. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	509.021	/	648.65
	=	0.78

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Seagen Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Seagen's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Seagen (Seagen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seagen Inc (NAS:SGEN) » Definitions » Inventory Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

21823 - 30th Drive South East, Bothell, WA, USA, 98021

Website

https://www.seagen.com

Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.

Executives

David R Epstein	director, officer: Chief Executive Officer	INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Vaughn B Himes	officer: See Remarks	C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Charles R Romp	officer: EVP, Commercial	21823 30TH DRIVE SE, BOTHELL WA 98021
Roger D Dansey	officer: See Remarks	21823 30TH DRIVE SE, BOTHELL WA 98021
Jean I Liu	officer: GC & EVP, Legal Affairs	21823 30TH DRIVE SE, BOTHELL WA 98021
Todd E Simpson	officer: Chief Financial Officer
Daniel G Welch	director	4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
David W Gryska	director	749 N MARY AVE, SUNNYVALE CA 94085
Sandra M Swain	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Ted W Love	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Clay B Siegall	director, officer: President and CEO	21823 30TH DR SE, BOTHELL WA 98021
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014